South Asian (n=90) | White (n=79) | ||||
Mean/Median | Range | Mean/Median | Range | p Value | |
Age (years) | 44 | 24–78 | 52 | 23–74 | 1.2×10–5 |
Sex (%male) | 73% | 61% | 0.08 | ||
Diabetes (%) | 42% | 37% | 0.52 | ||
BMI (kg/m2) | 28.6 | 19–42 | 32.8 | 23–52 | 4.0×10–8 |
Liver histology | |||||
Total NAS | 3 | 1–6 | 3 | 1–6 | 0.47 |
Steatosis | 1 | 1–3 | 1 | 1–3 | 0.89 |
Lobular inflammation | 1 | 0–2 | 1 | 0–2 | 0.01 |
Hepatocyte ballooning | 1 | 0–2 | 1 | 0–2 | 0.52 |
Fibrosis (Kleiner) | 1 | 0–4 | 1 | 0–4 | 0.60 |
Fibrosis stage (n) F0/F1/F2/F3/F4 | 34/23/11/15/17 | 28/23/5/12/11 | |||
Blood results | |||||
AST (U/l) | 47 | 10–140 | 48 | 16–133 | 0.75 |
ALT (U/l) | 76 | 13–262 | 69 | 12–288 | 0.37 |
Platelets x109/mL | 237 | 62–449 | 219 | 40–532 | 0.11 |
Albumin (g/L) | 46 | 28–53 | 45 | 33–52 | 0.04 |
Non-invasive liver tests | |||||
NAFLD fibrosis score | −2.34 | −5.8–3.4 | −1.31 | −6.1–3.0 | 4.0×10–4 |
APRI | 0.56 | 0.1–2.7 | 0.65 | 0.2–3.3 | 0.07 |
AST/ALT ratio | 0.70 | 0.3–2.0 | 0.77 | 0.3–1.7 | 0.13 |
BARD | 1 | 0–4 | 1 | 0–4 | 0.09 |
Fib-4 | 1.2 | 0.3–9.6 | 1.81 | 0.5–10.5 | 0.01 |
Characteristics are summarised as mean for continuous data (age, BMI, blood results, NAFLD fibrosis score, APRI, AST/ALT and Fib-4) and as median for categorical data (histology and BARD score). Two-tailed p values compare South Asian and white patients using Student’s t-test for continuous and the Mann-Whitney test for categorical data. Proportions of patients who are male and who have diabetes are compared using the χ2 test.
ALT, alanine aminotransferase; APRI, aspartate transaminase (AST) to platelet ratio index; AST, aspartate aminotransferase; BMI, body mass index; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD activity score.